Arca Biopharma Stock Analysis

ABIO
 Stock
  

USD 2.07  0.06  2.82%   

The latest Arca Biopharma price slide could raise concerns from institutional investors as the firm is trading at a share price of 2.07 on 59,800 in volume. The company directors and management were unable to exploit market volatilities in August. However, diversifying your overall positions with Arca Biopharma can protect your principal portfolio during market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 1.69. The below-average Stock volatility is a good sign for longer-term investment options and for buy-and-hold investors.
Please continue to Trending Equities.
  
The Arca Biopharma stock analysis report makes it easy to digest most publicly released information about Arca Biopharma and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Arca Biopharma Stock analysis module also helps to analyze the Arca Biopharma price relationship with some important fundamental indicators such as market cap and management efficiency.

Arca Biopharma Stock Analysis Notes

About 31.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.44. Some equities with similar Price to Book (P/B) outperform the market in the long run. Arca Biopharma recorded a loss per share of 2.07. The entity had not issued any dividends in recent years. The firm had 1:7 split on the 4th of April 2019. ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. The company was incorporated in 2004 and is headquartered in Westminster, Colorado. Arca Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 17 people. For more info on Arca Biopharma please contact Michael Bristow at 720 940 2200 or go to https://www.arcabio.com.

Arca Biopharma Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Arca Biopharma's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Arca Biopharma or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Arca Biopharma generated a negative expected return over the last 90 days
The company reported the previous year's revenue of 25.55 M. Net Loss for the year was (18.49 M) with profit before overhead, payroll, taxes, and interest of 28.37 M.
Arca Biopharma currently holds about 49.06 M in cash with (17.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.4, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Latest headline from www.etfstrategy.com: BlackRock launches neuroscience-focused healthcare ETF ETF Strategy - ETF Strategy

Arca Biopharma Upcoming and Recent Events

Earnings reports are used by Arca Biopharma to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Arca Biopharma previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report17th of March 2022
Next Fiscal Quarter End31st of December 2021

Arca Biopharma SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Arca Biopharma prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Arca Biopharma investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Arca Biopharma specific information freely available to individual and institutional investors to make a timely investment decision.
2nd of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
8th of July 2022
Unclassified Corporate Event
View
21st of June 2022
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Unclassified Corporate Event. Entry into a Material Definitive Agreement
View
27th of May 2022
Unclassified Corporate Event
View
11th of May 2022
Unclassified Corporate Event
View
5th of May 2022
Financial Statements and Exhibits. Other Events
View
2nd of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
18th of April 2022
Financial Statements and Exhibits. Other Events
View

Arca Biopharma Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Arca Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Arca Biopharma backward and forwards among themselves. Arca Biopharma's institutional investor refers to the entity that pools money to purchase Arca Biopharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Susquehanna International Group LlpPut Options882.9 K2.2 M
Vanguard Group IncCommon Shares460.2 K1.1 M
Blackrock IncCommon Shares264.3 K658 K
Susquehanna International Group LlpCommon Shares227.9 K568 K
Group One Trading LpCommon Shares131.5 K327 K
Susquehanna International Group LlpCall Options121.2 K302 K
Geode Capital Management LlcCommon Shares102.9 K256 K
State Street CorpCommon Shares71.6 K178 K
Millennium Management LlcCommon Shares59.4 K148 K
Note, although Arca Biopharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Arca Biopharma Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 30.69 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Arca Biopharma's market, we take the total number of its shares issued and multiply it by Arca Biopharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (19.25) % which means that it has lost $19.25 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (32.49) %, meaning that it created substantial loss on money invested by shareholders. Arca Biopharma management efficiency ratios could be used to measure how well arca biopharma manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 26th of September, Arca Biopharma shows the risk adjusted performance of (0.14), and Mean Deviation of 1.36. Arca Biopharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to collect and analyze data for nineteen technical drivers for Arca Biopharma, which can be compared to its rivals. Please confirm Arca Biopharma information ratio, and the relationship between the downside deviation and value at risk to decide if Arca Biopharma is priced correctly, providing market reflects its regular price of 2.07 per share. Please also double-check Arca Biopharma total risk alpha, which is currently at (0.15) to validate the company can sustain itself at a future point.

Arca Biopharma Price Movement Analysis

The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Arca Biopharma middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Arca Biopharma. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
.

Arca Biopharma Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Arca Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Arca Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Arca Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Funicular Fund Lp over a month ago via Macroaxis 
Arca Biopharma exotic insider transaction detected
Funicular Funds Lp over two months ago via Macroaxis 
Acquisition or disposition of Arca Biopharma securities by Funicular Funds Lp
Funicular Funds Lp over two months ago via Macroaxis 
Acquisition or disposition of Arca Biopharma securities by Funicular Funds Lp
Maweaver Jacob over three months ago via Macroaxis 
Arca Biopharma exotic insider transaction detected
Funicular Fund Lp over three months ago via Macroaxis 
Arca Biopharma exotic insider transaction detected
Funicular Fund Lp over three months ago via Macroaxis 
Arca Biopharma exotic insider transaction detected
Funicular Fund Lp over three months ago via Macroaxis 
Arca Biopharma exotic insider transaction detected
Funicular Fund Lp over three months ago via Macroaxis 
Arca Biopharma exotic insider transaction detected
Funicular Fund Lp over three months ago via Macroaxis 
Arca Biopharma exotic insider transaction detected
Funicular Fund Lp over three months ago via Macroaxis 
Purchase by Funicular Fund Lp of 57998 shares of Arca Biopharma
Funicular Fund Lp over three months ago via Macroaxis 
Arca Biopharma exotic insider transaction detected
Funicular Fund Lp over three months ago via Macroaxis 
Sale by Funicular Fund Lp of 7500 shares of Arca Biopharma

Arca Biopharma Predictive Daily Indicators

Arca Biopharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Arca Biopharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Arca Biopharma Forecast Models

Arca Biopharma time-series forecasting models is one of many Arca Biopharma's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Arca Biopharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Arca Biopharma Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Arca Biopharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Arca Biopharma shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Arca Biopharma. By using and applying Arca Biopharma Stock analysis, traders can create a robust methodology for identifying Arca Biopharma entry and exit points for their positions.
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. The company was incorporated in 2004 and is headquartered in Westminster, Colorado. Arca Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 17 people.

Current Arca Biopharma Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Arca Biopharma analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Arca Biopharma analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
16.5Strong Buy1Odds
Arca Biopharma current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Arca Biopharma analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Arca Biopharma stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Arca Biopharma, talking to its executives and customers, or listening to Arca Biopharma conference calls.
Arca Biopharma Analyst Advice Details

Arca Biopharma Stock Analysis Indicators

Arca Biopharma stock analysis indicators help investors evaluate how Arca Biopharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Arca Biopharma shares will generate the highest return on investment. By understating and applying Arca Biopharma stock analysis, traders can identify Arca Biopharma position entry and exit signals to maximize returns.
Quick Ratio18.04
Fifty Two Week Low1.7100
Shares Short Prior Month142.77k
Average Daily Volume Last 10 Day48.88k
Average Daily Volume In Three Month37.94k
Shares Percent Shares Out0.50%
Short Percent Of Float0.50%
Forward Price Earnings-0.24
Float Shares10.96M
Fifty Two Week High3.0000
Enterprise Value To Ebitda0.72
Fifty Day Average2.3544
Two Hundred Day Average2.2675
Please continue to Trending Equities. You can also try Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

Complementary Tools for analysis

When running Arca Biopharma price analysis, check to measure Arca Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arca Biopharma is operating at the current time. Most of Arca Biopharma's value examination focuses on studying past and present price action to predict the probability of Arca Biopharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Arca Biopharma's price. Additionally, you may evaluate how the addition of Arca Biopharma to your portfolios can decrease your overall portfolio volatility.
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Is Arca Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arca Biopharma. If investors know Arca Biopharma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arca Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Arca Biopharma is measured differently than its book value, which is the value of Arca Biopharma that is recorded on the company's balance sheet. Investors also form their own opinion of Arca Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Arca Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arca Biopharma's market value can be influenced by many factors that don't directly affect Arca Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arca Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Arca Biopharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arca Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.